Posted by Michael Wonder on 20 Dec 2019
Amgen and Allergan submit biologics license application for ABP 798, biosimilar candidate to Rituxan (rituximab), to U.S. FDA
19 December 2019 - Filing for ABP 798 supported by two comparative clinical studies.
Amgen and Allergan today announced the submission of a biologics license application to the U.S. FDA for ABP 798, a biosimilar candidate to Rituxan (rituximab).
Amgen and Allergan are collaborating on four oncology biosimilar medicines, two of which have already been approved by the FDA.
